13F Holdings
中文EN

SUPN Supernus, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1625297 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY16.3%
TTM net income YoY251.6%
TTM EPS YoY253.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin85.0%
Operating margin40.6%
Net margin32.8%
FCF margin2.3%
EBITDA margin41.1%

Returns

ROE—
ROA32.8%
ROIC (approx.)—
Asset turnover1.00x

Leverage & solvency

Liabilities / assets104.5%
Debt / equity—
Current ratio0.61x
Interest coverage32.82x

Cash quality & payout

Operating cash flow / net income0.21x
Accruals ratio25.8%
Payout ratio—
Capex / revenue4.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY2021*2021-12-31
Income statement
Revenue$1.24B$1.19B$1.09B$901.00M$791.00M
Cost of revenue$246.00M$231.00M$174.00M$151.00M$127.00M
Gross profit$994.00M$957.00M$919.00M$749.00M$664.00M
R&D expense$97.00M$107.00M$116.00M$74.00M$52.00M
SG&A expense$634.00M$612.00M$565.00M$469.00M$431.00M
Operating income$262.00M$38.00M-$152.00M-$81.00M$213.00M
Interest expense$45.00M$41.00M$35.00M$27.00M$27.00M
Pretax income$239.00M$20.00M-$145.00M-$89.00M$190.00M
Income tax$29.00M$13.00M-$19.00M-$44.00M-$15.00M
Net income$210.00M$7.00M-$126.00M-$44.00M$205.00M
EBITDA$272.00M$54.00M-$137.00M-$65.00M$228.00M
EPS (basic)1.680.05-0.92-0.32—
EPS (diluted)1.640.05-0.92-0.32—
Weighted avg. shares (diluted)128.00M133.00M137.00M139.00M151.94M
Balance sheet
Cash & equivalents$195.00M$319.00M$316.00M$774.00M$1.10B
Short-term investments$0$1.00M$94.00M——
Receivables$253.00M$254.00M$254.00M$220.00M$202.00M
Inventory$153.00M$167.00M$126.00M$114.00M$95.00M
Current assets$652.00M$827.00M$1.26B$1.26B$1.44B
PP&E, net$144.00M$100.00M$84.00M$54.00M$58.00M
Goodwill$2.00M$2.00M$5.00M——
Total assets$1.20B$1.32B$1.76B$1.77B$1.83B
Current liabilities$914.00M$924.00M$1.28B$1.02B$804.00M
Short-term debt$29.00M$18.00M$3.00M$3.00M$3.00M
Long-term debt$290.00M$315.00M$237.00M$237.00M$239.00M
Total debt$319.00M$333.00M$240.00M$240.00M$242.00M
Total liabilities$1.30B$1.65B$1.94B$1.72B$1.63B
Shareholders' equity-$98.00M-$337.00M-$184.00M-$15.00M$121.00M
Net debt$124.00M$14.00M-$76.00M-$534.00M-$860.00M
Cash flow statement
Operating cash flow-$27.00M$36.00M-$300.00M-$4.00M$353.00M
Capital expenditure$66.00M$29.00M$8.00M$5.00M$4.00M
Free cash flow-$93.00M$7.00M-$308.00M-$9.00M$349.00M
Investing cash flow-$66.00M$69.00M-$95.00M-$222.00M-$14.00M
Financing cash flow-$30.00M-$102.00M-$64.00M-$101.00M-$94.00M
Depreciation & amortization$10.00M$16.00M$15.00M$16.00M$15.00M
Stock-based compensation$26.00M$24.00M$21.00M$16.00M$11.00M
Share buybacks$11.00M$173.00M$33.00M$90.00M$101.00M

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.